Sanofi planning filings on top-line JAKARTA read-out
This article was originally published in Scrip
Executive Summary
Top-line results for the Phase III JAKARTA trial of Sanofi's JAK 2 inhibitor SAR302503 have come in positive and on schedule in myelofibrosis.